3.12 Patients must have measurable or evaluable disease. 
4.0 EXCLUSION CRITERIA 
The following conditions/situations will render patients ineligible for this study: 
4.1 Serious intercurrent medical illnesses, to include significant cardiac 
disease (New York Heart Association Class III or IV), angina pectoris, or 
myocardial infarction within the previous 6 months. 
4.2 The presence of an active infection, including urinary tract infection. 
4.3 The presence of active CNS metastases. 
' 
4.4 Pregnant or lactating women. 
i 
4.5 Patients who have received more than one form of immunosuppressive 
therapy to include radiotherapy or chemotherapy. 
4.6 Patients requiring continuing therapy with corticosteroids will not be 
eligible. 
5.0 CONCURRENT THERAPY 
i 
The following therapies are prohibited while patients are being treated on this protocol: 
radiation therapy, hormonal therapy, chemotherapy, corticosteroids (except as 
administered for life-threatening circumstances), or other immunotherapy. 
6.0 PRETREATMENT EVALUATION 
6. 1 History and physical examination, including documentation of all 
measurable disease. 
6.2 Height, weight, and performance status. 
6.3 Screening profile, BUN, and creatinine. 
6.4 CBC, differential, and platelet count. 
6.5 Chest X-ray. 
Recombinant DNA Research, Volume 15 
[925] 
